Association Between Administration of Ticagrelor and Microvascular Endothelial Function
Impaired endothelial function has been associated with an increased risk of adverse cardiovascular events, 1 while ticagrelor use has been associated with reduced risk. Ticagrelor's effect may be partially facilitated via adenosinemediated pleiotropic actions. Ticagrelor stimulates rapid release of adenosine triphosphate from red blood cells, inhibits adenosine uptake, and is associated with increased circulating adenosine levels in patients with acute coronary syndrome. 3 Ticagrelor administration has been shown to augment adenosine-induced coronary blood flow velocity and is associated with improved vascular reactivity compared with clopidogrel. 4 Our study aimed to describe the association between ticagrelor and vascular reactivity in relation to timing of drug administration.
Methods | In this prospective, open-label, clinical trial 5 of 45 par-
ticipants, we assessed the association of ticagrelor administration with endothelial function and arterial stiffness. The study was approved by Western University Research Ethics Board, and written informed patient consent was obtained. Inclusion criteria were an age of 18 years or older, coronary artery disease with at least 2 cardiovascular risk factors, and abnormal endothelial function defined as a reactive hyperemia index (RHI) of less than 2.0. Exclusion criteria were heart block, bleeding, stroke, dyspnea, valvular heart disease, anticoagulants, treatment with CYP3A4 inhibitors, alcohol or other drug abuse, liver disease, hypersensitivity to the study drug, pregnancy, and latex allergy.
Microvascular endothelial function was determined using a noninvasive assessment of endothelial function (EndoPAT2000; Itamar Medical Inc) as previously described. 6 Plethysmographic probes placed on the index fingers of each hand sense volume changes to measure peripheral arterial tonometry (PAT). The normalized augmentation index (AI75), a measure of arterial stiffness, was calculated from PAT waveforms recorded prior to cuff inflation using the formula (P2−P1)/P1, where P1 is the systolic peak and P2 is the reflected wave peak. The result is normalized to heart rate.
Reactive hyperemia index and AI75 were assessed in the absence of ticagrelor (baseline) and twice following ticagrelor administration for 21 days, at 12 hours after the last dose of ticagrelor (trough), and 2 hours after ticagrelor administration (peak). Prior revascularization includes both prior percutaneous coronary intervention and prior coronary artery bypass graft surgery. COPD indicates chronic obstructive pulmonary disease and PAD, peripheral arterial disease.
Letters
Continuous variables are summarized by mean and SD. Categorical variables are presented as counts and percentages. Continuous variables were compared using the paired t test or 1-way analysis of variance when appropriate. Discussion | We assessed endothelial function before and after a dose of ticagrelor, timed to reflect the drug's peak and trough levels. During peak ticagrelor levels, there was significant improvement in endothelial function compared with baseline and compared with the time of low drug levels. Reactive hyperemia index during trough was nonsignificantly higher compared to baseline. Considering the twice-daily drug administration, endothelial function may be improved during the dosing cycle of ticagrelor. However, this effect is not sustained for the duration of the 12 hours between drug dosing times and is maintained only while patients continue taking the drug. Our results contrast the lack of effect of ticagrelor therapy on reactive hyperemia in healthy young patients. 7 It is possible that the potential beneficial effect of ticagrelor is seen only in patients with established cardiovascular disease and endothelial dysfunction. The lack of effect of ticagrelor on arterial stiffness, measured simultaneously with RHI, underscores the fact that the effect on RHI is real and not related to repeated measurements. In conclusion, short-term administration of ticagrelor is associated with improvement in microvascular endothelial function. Use of ticagrelor did not affect arterial stiffness. 
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Reactive hyperemia index (A) and augmentation index normalized to heart rate (AI75) (B); at baseline visit and after treatment with ticagrelor at trough (12 hours after last dose) and peak (2 hours after ticagrelor administration) drug levels. The horizontal lines between the upper and lower whisker marks indicate the mean, while the top and bottom whisker marks represent SD. and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation or approval of the manuscript; and decision to submit the manuscript for publication. In their well-written research letter, the authors described the baseline prevalence and longitudinal incidence of conduction abnormalities and left ventricular dysfunction in a large single-center cohort of patients with myotonic muscular dystrophy type 1 and type 2 (DM1 and DM2). The authors defined left ventricular dysfunction (LVD) as an ejection fraction less than 55%, which differs from previous studies that used cutoffs of 50% or less. They reported a prevalence of left ventricular dysfunction at baseline in patients with DM1 of 11.8%, with an incidence of 2% during the follow-up period (mean, 5.76 years). The occurrence of left ventricular dysfunction in their DM1 cohort is much lower than those reported in previous studies. 
